NCT02532257View on ClinicalTrials.gov

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 11, 2016

Primary Completion Date

August 15, 2023

Study Completion Date

August 15, 2023

Conditions
Ann Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Marginal Zone LymphomaAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Marginal Zone LymphomaCD20 PositiveGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Janssen, LP

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02532257 - Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma | Biotech Hunter | Biotech Hunter